Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 1359 results for patients and public

  1. Pegzilarginase for treating arginase-1 deficiency [ID4029]

    In development [GID-HST10054] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  2. Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]

    In development [GID-TA11384] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development

  3. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327]

    In development [GID-TA11389] Expected publication date: 12 June 2024

    Technology appraisal guidance
    In development

  4. Eplontersen for treating polyneuropathy caused by hereditary transthyretin amyloidosis [ID6337]

    In development [GID-TA11392] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  5. Sirolimus for treating angiofibroma from tuberous sclerosis complex in people 6 years and older [ID3990]

    In development [GID-TA10883] Expected publication date: 18 September 2024

    Technology appraisal guidance
    In development

  6. Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130]

    In development [GID-HST10059] Expected publication date: 18 December 2024

    Highly specialised technologies guidance
    In development

  7. Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

    Awaiting development [GID-TA10165] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Sparsentan for treating primary IgA nephropathy ID6308

    In development [GID-TA11359] Expected publication date: 11 December 2024

    Technology appraisal guidance
    In development

  9. Iptacopan for treating paroxysmal nocturnal haemoglobinuria [ID6176]

    In development [GID-TA11132] Expected publication date: 26 June 2024

    Technology appraisal guidance
    In development

  10. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]

    In development [GID-TA11391] Expected publication date: 23 October 2024

    Technology appraisal guidance
    In development

  11. Anaphylaxis (QS119)

    This quality standard covers care after emergency treatment for suspected anaphylaxis, including assessment and referral to specialist allergy services. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    24 March 2016
    View quality statements

    Sections for QS119

  12. Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

    In development [GID-TA11117] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  13. Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

    In development [GID-TA11386] Expected publication date: 04 December 2024

    Technology appraisal guidance
    In development

  14. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]

    In development [GID-TA11369] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  15. Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]

    In development [GID-TA10980] Expected publication date: 17 July 2024

    Technology appraisal guidance
    In development